These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21211955)

  • 1. Reduction in perseverative errors with adjunctive ethyl-eicosapentaenoic acid in patients with schizophrenia: Preliminary study.
    Reddy R; Fleet-Michaliszyn S; Condray R; Yao JK; Keshavan MS; Reddy R
    Prostaglandins Leukot Essent Fatty Acids; 2011; 84(3-4):79-83. PubMed ID: 21211955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia.
    Fenton WS; Dickerson F; Boronow J; Hibbeln JR; Knable M
    Am J Psychiatry; 2001 Dec; 158(12):2071-4. PubMed ID: 11729030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol.
    Gallhofer B; Jaanson P; Mittoux A; Tanghøj P; Lis S; Krieger S
    Pharmacopsychiatry; 2007 Nov; 40(6):275-86. PubMed ID: 18030652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction.
    Kawai N; Yamakawa Y; Baba A; Nemoto K; Tachikawa H; Hori T; Asada T; Iidaka T
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1009-14. PubMed ID: 16644082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
    Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study.
    Rossi A; Mancini F; Stratta P; Mattei P; Gismondi R; Pozzi F; Casacchia M
    Acta Psychiatr Scand; 1997 Jan; 95(1):40-3. PubMed ID: 9051159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do schizophrenia patients make more perseverative than non-perseverative errors on the Wisconsin Card Sorting Test? A meta-analytic study.
    Li CS
    Psychiatry Res; 2004 Dec; 129(2):179-90. PubMed ID: 15590045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia.
    Emsley R; Myburgh C; Oosthuizen P; van Rensburg SJ
    Am J Psychiatry; 2002 Sep; 159(9):1596-8. PubMed ID: 12202284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risperidone treatment of schizophrenia: improvement in psychopathology and neuropsychological tests.
    Borkowska A; Araszkiewicz A; Rajewski A; Rybakowski JK
    Neuropsychobiology; 2002; 46(2):85-9. PubMed ID: 12378125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of verbalization strategy on Wisconsin Card Sorting Test performance in schizophrenic patients receiving classical or atypical antipsychotics.
    Rossi A; Daneluzzo E; Tomassini A; Struglia F; Cavallaro R; Smeraldi E; Stratta P
    BMC Psychiatry; 2006 Jan; 6():3. PubMed ID: 16438712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Red Yeast Rice on Cognitive Functioning in Schizophrenia: Data From a Pilot Study.
    Bruno A; Pandolfo G; Crucitti M; Troili GM; Battaglia F; Zoccali RA; Muscatello MRA
    J Clin Psychopharmacol; 2019; 39(3):210-213. PubMed ID: 30921099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study.
    Rémillard S; Pourcher E; Cohen H
    Schizophr Res; 2005 Dec; 80(1):99-106. PubMed ID: 16162401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does risperidone act better in schizophrenic patients who have a family or obstetric history?
    Borkowska A; Rybakowski JK
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Dec; 26(7-8):1349-53. PubMed ID: 12502024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial.
    Chung YC; Lee CR; Park TW; Yang KH; Kim KW
    World J Biol Psychiatry; 2009; 10(2):156-62. PubMed ID: 19514097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS?
    Weiser M; Shneider-Beeri M; Nakash N; Brill N; Bawnik O; Reiss S; Hocherman S; Davidson M
    Schizophr Res; 2000 Dec; 46(2-3):81-9. PubMed ID: 11120419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms.
    Peet M; Horrobin DF;
    J Psychiatr Res; 2002; 36(1):7-18. PubMed ID: 11755456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bergamot Polyphenolic Fraction Supplementation Improves Cognitive Functioning in Schizophrenia: Data From an 8-Week, Open-Label Pilot Study.
    Bruno A; Pandolfo G; Crucitti M; Cedro C; Zoccali RA; Muscatello MRA
    J Clin Psychopharmacol; 2017 Aug; 37(4):468-471. PubMed ID: 28591067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study.
    Frangou S; Lewis M; McCrone P
    Br J Psychiatry; 2006 Jan; 188():46-50. PubMed ID: 16388069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
    Mishara AL; Goldberg TE
    Biol Psychiatry; 2004 May; 55(10):1013-22. PubMed ID: 15121486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.